Halotestin 5mg
€ 49,00
5 mg · 100 tablets · Powerful oral research compound — Halotestin 5 mg delivers fluoxymesterone, a non-aromatising, high-AR-affinity steroid ideal for strength gain and CNS stimulation studies. Precision dosing and strong performance output make it ideal for lean-mass retention models with strict hepatotoxicity monitoring required.
Brand: Magnus Pharmaceuticals
Content: 100 tablets | 5 mg per tablet
Price: €49
Manufactured in: Europe
Halotestin 5 mg provides fluoxymesterone, a potent 17-α-alkylated, 9-fluoro androgenic steroid with roughly 5× the androgen-receptor (AR) affinity of testosterone. It’s a gold standard in strength-focused AAS research, particularly for muscle-performance modeling, neural drive stimulation, and non-estrogenic lean-mass retention.
Its small 5 mg dosing allows precision micro-administration in both low- and high-resolution sampling models. With ~100% oral bioavailability and a mean half-life of 9 hours, Halotestin is ideal for acute PK/PD trials involving strength output, aggression, and hormonal modulation—without estrogen conversion.
✅ Key Research HighlightsExplosive strength modeling: ~5× AR binding vs. testosterone supports peak-force output studies
Zero aromatisation: No estrogenic conversion — ideal for lean-gain without gynecomastia risks
Neural & aggression activation: Reported increases in CNS stimulation and workout aggression
Hepatic monitoring required: High risk of cholestatic jaundice and liver stress beyond 20 mg/day
WADA S1 banned: Any exposure yields a positive anti-doping result
🔬 Suggested Laboratory ApplicationsAndrogen-receptor pathway modeling
Non-estrogenic strength gain simulations
Lean muscle maintenance in caloric-restriction studies
CNS aggression and neural drive research
Hepatotoxicity and cholestasis mechanism analysis
📊 Technical Specifications| Field | Data |
|---|---|
| Chemical Name | Fluoxymesterone |
| Chemical Formula | C20H29FO3 |
| Synonyms | Halotestin; Ultandren; 9-Fluoro-11β,17β-dihydroxy-17-methyl-androst-4-en-3-one |
| Molecular Weight | 336.45 g/mol |
| CAS Number | 76-43-7 |
| Half-life (oral) | ~9 hours; peak plasma at ~1–2 h |
| PubChem Benefits | ↑ strength, ↑ neural drive, ↓ estrogen-mediated effects |
| Main Risks | Cholestatic liver injury, mood swings, HDL↓/LDL↑, hypertension |
| Total Active Compound | 500 mg fluoxymesterone per carton (5 mg × 100 tablets) |
| Shelf-life | 36 months (manufacturer specification) |
| Detection Window | ≥ 7 days; LC-MS/MS detects long-term urinary metabolites |
Fluoxymesterone increases maximal force output and lean-muscle density
Its non-aromatising structure eliminates estrogenic effects, such as fluid retention or gynecomastia
Stimulates androgen-driven CNS activity for enhanced aggression and neural activation
Documented use in androgen deficiency and ER+ cancer studies
Any fluoxymesterone exposure is a guaranteed WADA S1 violation
⚠️ Documented Research Side EffectsHepatocellular injury and cholestatic jaundice in extended protocols
Dyslipidaemia (HDL↓, LDL↑), acne, aggression, and hypertension
Elevated liver enzymes, especially >20 mg/day or 2+ weeks of use
Confirmed doping risk — banned across all tested competitive levels
🧯 Handling & ComplianceFor Research Use Only — Not for human or veterinary use
Store at 20–25°C, protect from light and moisture
Purchase confirms qualified researcher status
Listed on WADA Prohibited List S1 — any exposure triggers a positive test
Related products
Reviews
Clear filtersThere are no reviews yet.